



IFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/594,162
	Filing Date	September 26, 2006
	First Named Inventor	Bartsch
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	22393

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	USPTO Form 1449; References	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Dennis P. Tramaloni	
Signature		
Date	02/15/2007	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Dennis P. Tramaloni	
Signature		Date 02/15/2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

282978

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Pierre Bartsch, et. al.

Group:

Application No. 10/594,162, filed September 26, 2006
(Case Docket No. 22393)

Examiner:

For: PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
February 15, 2007

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1-A2, B1-B8 and C1-C38 are listed on Form PTO-1449. Documents B1-B8 and C1-C38 are enclosed. Documents A1-A2 are not being submitted because they are US Patents.

Consideration of all the documents cited on Form PTO-1449 is requested.

Appl. No. 10/594,162
Filed: September 26, 2006


Since the Information Disclosure Statement is submitted before the receipt of the first Office Action on the merits for the above application, it is believed that no fee is due. If a fee is due and owing, please charge to Deposit Account No. 08-2525.

Respectfully submitted,



Attorney for Applicant(s)
Dennis P. Tramaloni
(Reg. No. 28,542)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4475
Telefax: (973) 235-2363

282976



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Complete if Known

Application Number	10/594,162
Filing Date	September 26, 2006
First Name Inventor	Bartsch
Group Art Unit	
Examiner Name	
Attorney Docket Number	22393

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	6,110,924		Bosies, et. al.	08-29-2000
	A2	6,242,455		Grams, et. al.	06-05-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1		WO 98/58915		Boehringer Mannheim GMBH	12-30-1998	
	B2		WO 00/40962		KOSAK	07-13-2000	
	B3		WO 01/25217		F. Hoffmann-La Roche AG	04-12-2001	
	B4		WO 02/089824		F. Hoffmann-La Roche AG	11-14-2002	
	B5		WO 97/23465		Boehringer Mannheim GMBH	07-03-1997	
	B6		WO 00/37109		Euphar Group SRL	06-29-2000	
	B7		WO 2005/097058		Hoffmann-La Roche AG	10-20-2005	
	B8		EP 1 018 340		Tecnimed-Sociedade Technico-Medicinal	07-12-2000	
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/594,162
				Filing Date	September 26, 2006
				First Name Inventor	Bartsch
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	3	Attorney Docket Number	22393

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Egeblad, M., and Werb, Z., Nat. Rev. Cancer 2 (2002) 161-174;	
	C2	Overall, C.M., and Lopez-Otin, C., Nat. Rev. Cancer 2 (2002) 657-672	
	C3	Holmbeck, K., et al., Cell 99 (1999) 81-92	
	C4	Vu, T.H., et al., Cell 93 (1998) 411-422	
	C5	Shapiro, S.D., Curr. Opin. Cell Biol. 10 (1998) 602-608	
	C6	Lund, L.R., et al., EMBO J. 18 (1999) 4645-4656	
	C7	Carmeliet, P., et al., Nat. Genet. 17 (1997) 439-444	
	C8	Chang, C., and Werb, D., Trends Cell Biol. 11 (2001) S37-43	
	C9	Manes, S., et al., J. Biol. Chem. 274 (1999) 6935-6945	
	C10	Bergers, G., et al., Nat. Cell Biol. 2 (2000) 737-744	
	C11	Dong, Z., et al., Cell 88 (1997) 801-810	
	C12	Janowska-Wieczorek, A., et al., Blood 93 (1999) 3379-3390	
	C13	Carstensen, D., et al., Transfusion 42 (2002) 588-596	
	C14	Grams, F., et al., Biol. Chem. 382 (2001) 1277-1285	
	C15	Ansel, H., et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed., (1995), pp. 196 and 1456-1457	
	C16	Fabbri, L.M., and Hurd, S.S., Eur. Respir. J. 22 (2003) 1-2	
	C17	Higuchi, T., and Connors, K.A., Advances in Analytical Chemistry and Instrumentation 4 (1965) 117-212	
	C18	Yu, Z., and Westerlund, D., Chromatographia 44 (1997) 589-594	
	C19	Hubert, Ph., et al., S. T. P. Pharma Pratiques 9 (1999) 160-180	
	C20	Souverain, S., et al., Journal of Chromatography B 801 (2004) 141-156)	
	C21	Chiap, P., et al., Journal of Chromatography B 817 (2005), 109-117	
	C22	Hubert, P., et al., Analytica Chimica Acta 391 (1999) 135-148;	
	C23	Hubert, Ph., et al., J. Pharm. Biomed. Anal. 36 (2004) 579-586	
	C24	Hamelmann, E., et al., Am. J Respir. Crit. Care Med. 156 (1997) 766-775	
	C25	Cataldo, D.D., et al, Am. J. Pathol. 161 (2002) 491-498	
	C26	Aki, et al. Jour of Pharm Sci, V. 90 (2001) 1186-1197	
	C27	Csabai, Int Jour of Pharm 91 (1993) 15-22	
	C28	Foley, Bio & Med Chem Ltr (2001) 969-972	
	C29	Kotzumi, 94 (1974) 1515	
	C30	Lopata, Jour of Phar Sci, 74 (1985) 211-213	



	C31	Mura, Eur Jour of Pharm (2005) 99-106	
	C32	Piel, Jour of Pharm Sci, 86 (1997) 475-480	
	C33	Szejtli, Cyclodextrin Tech (1988) 186-307	
	C34	Iwaoku, Chem Pharm Bull (1982) 1416-1421	
	C35	Loukas, Int Jour of Pharm 226 (2001) 207-211	
	C36	Suzuki, Chem Pharm Bull (1993) 1444-1447	
	C37	Lein, Oncogene (2002) 2089-2096	
	C38	Mura, Int Jour Pharm 260 (2003) 293-302	
Examiner Signature			DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or abstract is attached.

257509